tradingkey.logo

Biomerica Inc

BMRA
2.250USD
-0.020-0.88%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
6.63MMarktkapitalisierung
VerlustKGV TTM

Biomerica Inc

2.250
-0.020-0.88%

mehr Informationen über Biomerica Inc Unternehmen

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

Biomerica Inc Informationen

BörsenkürzelBMRA
Name des UnternehmensBiomerica Inc
IPO-datumMar 17, 1980
CEOIrani (Zackary S)
Anzahl der mitarbeiter53
WertpapierartOrdinary Share
GeschäftsjahresendeMar 17
Addresse17571 Von Karman Avenue
StadtIRVINE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92614
Telefon19493792875
Websitehttps://biomerica.com/
BörsenkürzelBMRA
IPO-datumMar 17, 1980
CEOIrani (Zackary S)

Führungskräfte von Biomerica Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+52500.00%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+40000.00%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+20000.00%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+22500.00%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Madel
Mr. Scott Madel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Gary M. Huff
Mr. Gary M. Huff
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+52500.00%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+40000.00%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+20000.00%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+22500.00%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%
Nach RegionUSD
Name
Umsatz
Anteil
Asia
670.00K
48.55%
United States
318.00K
23.04%
Europe
305.00K
22.10%
Middle East
85.00K
6.16%
South America
2.00K
0.14%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%

Aktionärsstatistik

Aktualisiert: Sun, Jan 25
Aktualisiert: Sun, Jan 25
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
Andere
85.94%
Aktionäre
Aktionäre
Anteil
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
Andere
85.94%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
15.59%
Investment Advisor
1.98%
Investment Advisor/Hedge Fund
0.76%
Hedge Fund
0.35%
Research Firm
0.03%
Andere
81.28%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
61
88.80K
11.10%
--
2025Q3
66
109.78K
12.53%
+19.30K
2025Q2
64
90.48K
15.22%
-57.30K
2025Q1
68
147.78K
21.33%
-341.18K
2024Q4
67
244.57K
22.09%
-15.39K
2024Q3
66
259.96K
25.76%
-100.07K
2024Q2
66
360.04K
29.98%
-224.63K
2024Q1
64
584.66K
28.76%
-20.09K
2023Q4
60
562.02K
30.44%
-39.83K
2023Q3
60
602.09K
33.14%
-52.42K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Irani (Zackary S)
219.13K
7.43%
+52.50K
+31.51%
Dec 12, 2025
Barbieri (Allen)
67.29K
2.28%
+30.00K
+80.44%
Dec 12, 2025
Lu (Gary)
64.53K
2.19%
+40.00K
+163.05%
Dec 12, 2025
Moatazedi (David)
41.25K
1.4%
+20.00K
+94.12%
Dec 12, 2025
Chin (Eric)
10.00K
0.34%
--
--
Oct 17, 2025
Emerson (Jane)
30.13K
1.02%
+30.13K
--
Oct 17, 2025
The Vanguard Group, Inc.
21.13K
0.72%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
20.98K
0.71%
-680.00
-3.14%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
18.64K
0.63%
--
--
Sep 30, 2025
Coste (Catherine)
16.10K
0.55%
+10.63K
+194.10%
Dec 13, 2024
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Apr 16, 2025
Merger
8→1
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 16, 2025
Merger
8→1
KeyAI